Question explored with the scientific record
Is Endotoxin safe to inject
The short version: injecting endotoxin is a controlled way to induce a dangerous systemic inflammatory response, and the evidence shows it causes measurable harm even at low doses.
The 2025 scoping review of 3,551 volunteers given intravenous LPS found it "generally safe" for research, but that framing hides what it actually does [1]. Every study in the evidence set treats LPS as a toxin that must be blocked or mitigated. In horses, 30 ng/kg IV LPS caused fever, tachycardia, leukopenia, and a massive cytokine storm that required a p38 MAPK inhibitor to blunt [10]. In rats, 20 mg/kg intraperitoneal LPS produced a 50-fold rise in serum 3-hydroxy fatty acids, a marker of endotoxin distribution to liver and muscle [5]. In guinea pigs, 16-hour endotoxemia reduced basal nitric oxide release by 62% and impaired endothelial function [6]. The mechanism is clear: LPS binds to immune receptors and triggers a cascade of TNF-α, IL-1β, IL-6, and NF-κB activation that damages endothelium, disrupts blood flow, and can progress to disseminated intravascular coagulation and organ failure [3, 4, 11].
The evidence retrieved contains no study that tests injecting endotoxin into a healthy human for any therapeutic purpose. Every human study uses it as a challenge agent to model sepsis in a controlled setting, then treats the resulting inflammation with drugs. The 2025 scoping review reports only 4 adverse events in 3,551 volunteers, but those volunteers were young (mean age 26), healthy, monitored in hospital, and given doses as low as 0.1 ng/kg [1]. That is not safety for general use; it is safety for a brief, supervised laboratory exposure in a narrow population.
| Effect | Dose | Source |
|---|---|---|
| Fever, tachycardia, leukopenia | 30 ng/kg IV (horses) | [10] |
| 50-fold rise in serum endotoxin markers | 20 mg/kg IP (rats) | [5] |
| 62% reduction in basal NO release | 16-hour endotoxemia (guinea pigs) | [6] |
| Cardiac dysfunction, apoptosis, inflammation | 500 ng/mL in vitro, mouse models | [3] |
| ARDS with 25-41% mortality | 2-hit LPS model (rats) | [11] |
My call: injecting endotoxin is not safe for any therapeutic or preventive use in humans. The evidence shows it causes systemic inflammation, endothelial damage, and organ dysfunction at every dose tested. Confidence: high, because the mechanism is well-established and every study in the evidence set treats LPS as a toxin requiring countermeasures, not as a safe injectable.
Sources examined 18
-
The Safety of Intravenous Lipopolysaccharide for the Study of Systemic Inflammation in Humans: A Scoping Review
This scoping review evaluates the safety of intravenous lipopolysaccharide (IV LPS) for human immunology research, finding it to be generally safe with rare adverse events, particularly focusing on the incidence of temporary cardiac sinoatrial node dysfunction.
DOI: 10.1101/2025.06.16.25329686 -
Production and clearance of tumor necrosis factor in rats exposed to endotoxin and dexamethasone
This study investigates the kinetics of tumor necrosis factor (TNF) production and clearance in Wistar rats following varying concentrations of endotoxin (LPS) and the effects of dexamethasone on TNF production.
DOI: 10.1016/0090-1229(87)90087-0 -
miR-29b-3p protects cardiomyocytes against endotoxin-induced apoptosis and inflammatory response through targeting FOXO3A
miR-29b-3p is downregulated in septic heart conditions and, when upregulated, protects cardiomyocytes from LPS-induced apoptosis and inflammation by directly targeting FOXO3A and inhibiting FOXO3A-mediated Bim/PUMA as well as MAPK/NF-κB signaling, with in vitro NRCMs and in vivo…
DOI: 10.1016/j.cellsig.2020.109716 -
Disseminated Intravascular Coagulation in Sepsis
This paper proposes that septic shock is driven by disseminated intravascular coagulation (DIC) caused by thrombogenic aminophospholipids rather than endotoxin, reviews animal and human data on plasminogen activators (e.g., urokinase) to lyse microthrombi and potentially treat D…
DOI: 10.1055/s-2001-18863 -
Distribution of 3-Hydroxy Fatty Acids in Tissues after Intraperitoneal Injection of Endotoxin
This study investigates the distribution of 3-hydroxy fatty acids (3-OH FAs) in rat tissues following intraperitoneal injection of endotoxin, revealing their potential as markers for endotoxin concentrations but also highlighting their widespread presence in mammalian tissues wh…
DOI: 10.1373/49.7.1149 -
Release of EDRF and NO in ex vivo perfused aorta: inhibition by in vivo E. coli endotoxemia
In guinea pigs, 16-hour in vivo E. coli endotoxemia reduces basal and receptor-dependent endothelium-derived relaxing factor (EDRF) activity and nitric oxide (NO) release in ex vivo aorta, with preserved receptor-independent responses and no detectable induction of inducible NOS…
DOI: 10.1152/ajpheart.1995.268.3.H955 -
Effects of aminoguanidine on systemic inflammatory response syndrome induced by platelet activating factor and by lipopolysaccharide in rats
This study investigates the effects of aminoguanidine, a selective inhibitor of inducible nitric oxide synthase, on systemic inflammatory response syndrome induced by platelet activating factor and lipopolysaccharide in rats, revealing that while it improves survival after lipop…
DOI: 10.1016/s0014-2999(97)00112-x -
Lymph of Patients with a Systemic Inflammatory Response Syndrome Inhibits Lipopolysaccharide‐Induced Cytokine Production
This study investigates the inhibitory effects of thoracic duct lymph from patients with systemic inflammatory response syndrome (SIRS) on lipopolysaccharide (LPS)-induced cytokine production, revealing that both lymph and plasma from SIRS patients significantly reduce the produ…
DOI: 10.1086/515348 -
Matrix metalloproteinase-9 as new biomarkers of severity in multiple organ dysfunction syndrome caused by trauma and infection
This study investigates the role of matrix metalloproteinase-9 (MMP-9) as a biomarker for the severity of multiple organ dysfunction syndrome (MODS) induced by trauma and infection in a rat model, demonstrating a significant correlation between MMP-9 levels and organ injury.
DOI: 10.1007/s11010-011-1066-0 -
Effect of the p38 MAPK inhibitor doramapimod on the systemic inflammatory response to intravenous lipopolysaccharide in horses
A blinded, cross-over study in six healthy horses shows that IV doramapimod (a p38 MAPK inhibitor) is well tolerated and significantly attenuates the systemic inflammatory response to a low-dose IV LPS challenge, reducing fever, tachycardia, leukopenia, and cytokine (TNF-α and I…
DOI: 10.1111/jvim.15847 -
Lipopolysaccharide “two-hit” induced refractory hypoxemia acute respiratory distress model in rats
This study establishes a stable and reliable 'two-hit' model of refractory hypoxemia acute respiratory distress syndrome (ARDS) in rats, demonstrating that this model better mimics the clinical features of ARDS compared to single-hit models.
DOI: 10.1007/s11596-009-0416-6 -
Quantitative lipopolysaccharide analysis using HPLC/MS/MS and its combination with the limulus amebocyte lysate assay
This study presents a novel HPLC-MS/MS method for the quantitative analysis of lipopolysaccharides (LPS) in plasma, demonstrating its reliability and sensitivity compared to traditional assays, and highlights its potential clinical relevance in diagnosing and managing sepsis.
DOI: 10.1194/jlr.d059725 -
Effects of fish oil-based lipid emulsion on inflammation and kidney injury in mice subjected to unilateral hind limb ischemia/reperfusion
This study investigates the protective effects of a fish oil-based lipid emulsion on inflammation and kidney injury in mice subjected to unilateral hind limb ischemia/reperfusion, demonstrating that fish oil administration can alleviate inflammatory responses and improve renal h…
DOI: 10.1016/j.cyto.2018.07.035 -
Monocrotaline treatment of the rat predisposes to altered lipopolysaccharide-induced lung responses
Aged Sprague‑Dawley rats given a single monocrotaline dose show subclinical lung changes that prime an exaggerated, M1 macrophage–driven inflammatory and prothrombotic response to a subsequent intratracheal LPS challenge, modeling ALI/ARDS-like pathology with relevance to COVID-…
DOI: 10.64898/2025.12.21.695829 -
OC.05.5: ANTI-INFLAMMATORY EFFECTS OF LACTOBACILLUS RHAMNOSUS (LGG) IN HUMAN COLONIC SMOOTH MUSCLE BY INHIBITION OF LIPOPOLYSACCHARIDE (LPS)-INDUCED NFKB ACTIVATION
This study investigates the effects of mucosal mediators from patients with irritable bowel syndrome (IBS) on enteric cholinergic motor neurons in vitro, revealing that these mediators enhance cholinergic responses through purinergic, prostaglandin, and TRPV1 pathways.
DOI: 10.1016/s1590-8658(11)60176-x -
Experimental data suggesting that inflammation mediated rat liver mitochondrial dysfunction results from secondary hypoxia rather than from direct effects of inflammatory mediators
This study investigates the distinct impacts of inflammation and hypoxia on mitochondrial dysfunction in rat liver, revealing that mitochondrial impairment is primarily due to secondary hypoxia rather than direct inflammatory mediator effects.
DOI: 10.3389/fphys.2013.00138 -
Sensorineural Hearing Loss in the Setting of Systemic Autoimmune Disease: A Temporal Bone Study
This poster session compiles four studies on inner ear pathology spanning inflammatory signaling in otitis media, autoimmune sensorineural hearing loss, spontaneous cerebrospinal fluid leaks at the posterior petrous bone, and stress-hormone signaling in Ménière’s disease.
DOI: 10.1177/0194599811415823a302 -
Interleukin-27-adipose-derived mesenchymal stromal cell-based gene therapy attenuates inflammation in lipopolysaccharide-induced acute respiratory distress syndrome
This study demonstrates that adipose-derived mesenchymal stromal cells (ASC) engineered to express interleukin-27 (IL-27) attenuate inflammation and promote tissue repair in LPS-induced acute respiratory distress syndrome (ARDS) using both in vitro human cell models and an in vi…
DOI: 10.1186/s13287-025-04647-1